CLNN:NSD-Clene Inc (USD)

COMMON STOCK | | NSD

Last Closing Price

USD 8.28

Change

-0.34 (-3.94)%

Market Cap

USD 0.52B

Volume

0.13M

Avg Analyst Target

USD 21.33 (+157.65%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean surfaced nanotechnology (CSN) therapeutics. The company has a nanotechnology drug suspension; and engages in the development and commercialization of dietary supplements. Its lead drug is CNM-Au8, which is being studied in various clinical trials, including a Phase 2 study for the treatment of stable multiple sclerosis; a Phase 2 biomarker study in Parkinson's; and Phase 2 and Phase 3 trials to investigate the potential for disease modification for neurodegenerative diseases. The company's products also include CNM-AgZn17, a topical gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to accelerate wound healing; CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat disease-causing infections, such as COVID-19 and to provide immune support for symptom resolution; and CNM-PtAu7, a gold-platinum CSN therapeutic for oncology applications. Clene Inc. is headquartered in Salt Lake City, Utah.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-08-03 )

Largest Industry Peers for

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
ARVLW Arrival

N/A

USD10.04B N/A N/A
CHKEZ Chesapeake Energy Corporation

+0.44 (+1.79%)

USD5.28B N/A N/A
CHKEL Chesapeake Energy Corporation

-0.49 (-2.18%)

USD5.28B N/A N/A
CHKEW Chesapeake Energy Corporation

-0.56 (-1.93%)

USD5.28B N/A N/A
BOKFL BOK Financial Corporation

-0.01 (-0.04%)

USD5.22B 3.39 N/A
CLOVW Clover Health Investments, Cor..

-0.05 (-2.44%)

USD5.15B N/A N/A
ADVWW Advantage Solutions Inc

N/A

USD3.69B N/A N/A
ATCOL Atlas Corp

+0.20 (+0.76%)

USD3.36B 39.97 N/A
HCACW Hennessy Capital Acquisition C..

N/A

USD3.34B 11.29 N/A
TCBIL Texas Capital Bancshares, Inc

N/A

USD2.88B 8.83 N/A

ETFs Containing CLNN

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification ()
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 12 Months  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) N/A N/A N/A N/A N/A
Risk Adjusted Return N/A N/A N/A N/A N/A
Market Capitalization 0.52B N/A N/A 54% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
()
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 1,272.57 N/A N/A 0% N/A
Price / Cash Flow Ratio -27.50 N/A N/A 83% B
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -456.75% N/A N/A 11% F
Return on Invested Capital 61.09% N/A N/A 97% A+
Return on Assets -48.64% N/A N/A 4% F
Debt to Equity Ratio 571.55% N/A N/A 3% F
Technical Ratios  
Short Ratio 1.45 N/A N/A 67% D+
Short Percent 7.86% N/A N/A 26% F
Beta N/A N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Negative cashflow

The company had negative total cash flow in the most recent four quarters.